Takeda (TSE:4502/NYSE:TAK) today announced positive data from the pivotal Phase 3 KEPLER trial, which demonstrated that ENTYVIO ® (vedolizumab) can offer the possibility of clinical remission for ...
Alvotech (NASDAQ:ALVO) is one of the Best Penny Stocks That Will Skyrocket. On February 5, Alvotech (NASDAQ:ALVO) announced ...
Takeda Pharmaceutical (TSE:4502) reported positive Phase 3 data for ENTYVIO in pediatric ulcerative colitis patients. The company also received US FDA Priority Review for TAK-861, a novel treatment ...
Fresenius Kabi is expanding its growing biopharma portfolio through a new licensing agreement with Polpharma Biologics S.A. Fresenius Kabi will commercialize Polpharma Biologics’ vedolizumab ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results